Novartis raised its combined peak sales forecast for three medicines to $18 billion from $14 billion, according to a report published on November 19, 2026. The Swiss drugmaker cited stronger commercial performance for multiple sclerosis treatment Kesimpta, leukaemia treatment Scemblix and cholesterol medicine Leqvio.
CEO Vas Narasimhan pointed to growing market share for Kesimpta and Scemblix and strong demand for Leqvio in the U.S. and Asia. Novartis shares were down 2.4% in mid-morning trading in Switzerland at the time of the report.
Despite the higher forecasts for those drugs, Novartis projected annual sales growth of 5% through 2031, compared with its previous guidance of 5% to 6% through 2030. The forecasts cover different periods. Narasimhan said the revised outlook reflected expected U.S. generic competition for breast cancer treatment Kisqali in the second half of 2031.
Citi analysts said the 2031 sales guidance was about 3% above consensus, but expected investors to remain skeptical about growth after 2031 pending more data from Novartis’s drug pipeline.
The outlook follows clinical setbacks reported in September 2026: a trial of cardiovascular drug pelacarsen failed to show improved cardiovascular outcomes, and the experimental treatment del-desiran failed in a late-stage trial for a muscle-wasting disorder. Narasimhan defended Novartis’s capital allocation strategy after the del-desiran result. The company had acquired the drug through a $12 billion deal for Avidity Biosciences earlier in 2026.
